Healthcare Bearish Stocks: China Cord Blood Corp (NYSE:CO), Arrowhead Research Corp (NASDAQ:ARWR), AVEO Pharmaceuticals (NASDAQ:AVEO), Celldex Therapeutics (NASDAQ:CLDX), Zogenix (NASDAQ:ZGNX)

On 18 JUNE China Cord Blood Corp (NYSE:CO) announced its preliminary unaudited financial results for the fourth quarter and 2014 fiscal year ended March 31, 2014. Revenues for the fourth quarter of fiscal 2014 increased to RMB151.9 million ($24.4 million) from
RMB133.0 million in the prior year period. Gross profit increased to RMB124.6 million ($20.0 million) from RMB106.1 million in the prior year period. China Cord Blood Corp (NYSE:CO) net profit margin is 23.10% and weekly performance is -21.38%. On last trading day company shares ended up $4.34. Analysts mean target price for the company is $6.33. China Cord Blood Corp (NYSE:CO) distance from 50-day simple moving average (SMA50) is -7.05%.

On 20 JUNE Arrowhead Research Corp (NASDAQ:ARWR) reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.11. Analysts expect that Arrowhead Research Corp will post $-0.92 EPS for the current fiscal year. Arrowhead Research Corp (NASDAQ:ARWR) shares fell -8.06% in last trading session and ended the day on $11.40. ARWR return on assets is -47.50%. Arrowhead Research Corp (NASDAQ:ARWR) quarterly performance is -31.86%.

On 1 JULY AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) said it has seen two positive estimate revisions over the past 30 days and its Zacks Consensus Estimate has moved higher over the same time frame, suggesting that more solid trading could be ahead for AVEO Pharmaceuticals. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares moved down -9.76% in last trading session and was closed at $1.48, while trading in range of $1.47 – $1.62. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) year to date (YTD) performance is -19.13%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended the last trading day at $14.57. Company weekly volatility is calculated as 7.93% and price to cash ratio as 4.75. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a negative weekly performance of -10.72%.

Zogenix, Inc. (NASDAQ:ZGNX) said that Purdue Pharma Inc L.P. has received a priority review from the Food and Drug Administration (FDA) for its abuse-resistant painkiller. A priority review reduces the time it takes the FDA to approve a drug from ten months to six. Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is -7.46%. On last trading day company shares ended up $1.86. Analysts mean target price for the company is $4.48. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -11.50%.